Literature DB >> 17473526

[Endothelial progenitor cells for vascular medicine].

Takayuki Asahara1.   

Abstract

The regenerative potential of stem cells has recently been under intense investigation. In vitro, stem and progenitor cells have the ability for self-renewal and differentiation into organ-specific cell types. In vivo, transplantation of these cells may reconstitute organ systems, as shown in animal models of disease. In contrast, differentiated cells do not exhibit such characteristics. Human endothelial progenitor cells (EPCs) have been isolated from the peripheral blood of adult individuals, expanded in vitro and committed to an endothelial lineage in culture. The transplantation of these human EPCs has been shown to facilitate successful salvage of limb vasculature and perfusion in athymic nude mice with severe hindlimb ischemia, while differentiated endothelial cells (human microvascular endothelial cells) failed to accomplish limb-saving neovascularization. Future studies will clarify the mechanisms and circumstances that may be responsible for modulating the contribution of vasculogenesis to postnatal neovascularization. Specifically in this regard, it is intriguing to consider the possibility that certain angiogenic growth factors acknowledged to promote both angiogenesis and vasculogenesis in the embryo, but have been assumed to promote neovascularization exclusively by angiogenesis in the adult, may in fact promote migration, proliferation, and mobilization of EPCs from bone marrow. The possibility that modulation of vasculogenesis can be used therapeutically to augment as well as inhibit neovascularization deserves further investigation.

Entities:  

Mesh:

Year:  2007        PMID: 17473526     DOI: 10.1248/yakushi.127.841

Source DB:  PubMed          Journal:  Yakugaku Zasshi        ISSN: 0031-6903            Impact factor:   0.302


  7 in total

1.  The matricellular protein cysteine-rich protein 61 (CCN1/Cyr61) enhances physiological adaptation of retinal vessels and reduces pathological neovascularization associated with ischemic retinopathy.

Authors:  Adeel Hasan; Nataliya Pokeza; Lynn Shaw; Hyun-Seung Lee; Douglas Lazzaro; Hemabindu Chintala; Daniel Rosenbaum; Maria B Grant; Brahim Chaqour
Journal:  J Biol Chem       Date:  2011-01-06       Impact factor: 5.157

Review 2.  Strategies for ensuring that regenerative cardiomyocytes function properly and in cooperation with the host myocardium.

Authors:  Fumiyuki Hattori; Keiichi Fukuda
Journal:  Exp Mol Med       Date:  2010-03-31       Impact factor: 8.718

3.  Mechanical strain activates a program of genes functionally involved in paracrine signaling of angiogenesis.

Authors:  Ru Yang; Jawaria Amir; Haibo Liu; Brahim Chaqour
Journal:  Physiol Genomics       Date:  2008-10-14       Impact factor: 3.107

4.  Endothelial progenitor cells promote directional three-dimensional endothelial network formation by secreting vascular endothelial growth factor.

Authors:  Yoshinori Abe; Yoshiyuki Ozaki; Junichi Kasuya; Kimiko Yamamoto; Joji Ando; Ryo Sudo; Mariko Ikeda; Kazuo Tanishita
Journal:  PLoS One       Date:  2013-12-03       Impact factor: 3.240

5.  S-allylcysteine Improves Blood Flow Recovery and Prevents Ischemic Injury by Augmenting Neovasculogenesis.

Authors:  Jia-Ning Syu; Mei-Due Yang; Shu-Yao Tsai; En-Pei Isabel Chiang; Shao-Chih Chiu; Che-Yi Chao; Raymond L Rodriguez; Feng-Yao Tang
Journal:  Cell Transplant       Date:  2017-10       Impact factor: 4.064

6.  Development of a Novel Pre-Vascularized Three-Dimensional Skin Substitute Using Blood Plasma Gel.

Authors:  Niann-Tzyy Dai; Wen-Shyan Huang; Fang-Wei Chang; Lin-Gwei Wei; Tai-Chun Huang; Jhen-Kai Li; Keng-Yen Fu; Lien-Guo Dai; Pai-Shan Hsieh; Nien-Chi Huang; Yi-Wen Wang; Hsin-I Chang; Roxanne Parungao; Yiwei Wang
Journal:  Cell Transplant       Date:  2018-09-11       Impact factor: 4.064

Review 7.  From Grafts to Human Bioengineered Vascularized Skin Substitutes.

Authors:  Wasima Oualla-Bachiri; Ana Fernández-González; María I Quiñones-Vico; Salvador Arias-Santiago
Journal:  Int J Mol Sci       Date:  2020-11-02       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.